Results of a Phase II randomized trial published Online First in The Lancet, reveal that a new treatment for type 2 diabetes called TAK-875, enhances glycemic (blood sugar) control and is just as effective as the common drug treatment - sulphonylurea glimepiride. In addition, TAK-875 has less adverse effects and a considerably lower risk of hypoglycemia (low blood sugar)...
No comments:
Post a Comment